コラム
Hair Loss Medicines in Japan: Finasteride, Dutasteride and Minoxidil Compared
This guide to Hair loss medicines in Japan covers AGA medicine classes, combination products and diagnosis-specific treatment. It separates medicine-specific information from the product and prescription checks needed for an individual consultation.
This page explains how AGA treatment overview works, its directions, limitations and safety. For prices and individual prescriptions, see SWIFT’s relevant care information.
AGA treatment selects progression-suppressing medicines or topical hair-growth products according to the diagnosis. Do not choose online purchasing by medicine name alone; check approval, ingredients, assessment timing and side effects. Combinations containing oral minoxidil, unapproved in Japan, require a separate explanation.
Medical reviewer: Masashi Morita, MD
AGA treatment selects progression-suppressing medicines or topical hair-growth products according to the diagnosis. Do not choose online purchasing by medicine name alone; check approval, ingredients, assessment timing and side effects. Combinations containing oral minoxidil, unapproved in Japan, require a separate explanation.
- Ingredient/class
- Finasteride, dutasteride and minoxidil
- Eligible patients/indications
- Distinguish male pattern hair loss from female pattern hair loss, alopecia areata and sudden shedding. Do not repurpose male AGA 5α-reductase inhibitors for women.
- Assessing effects
- Finasteride and dutasteride effects are usually assessed after approximately 6 months of continued use. Follow each topical product’s assessment period too, comparing consistent photographs and examination findings. Periodically assess need rather than continuing indefinitely.
- Clinic care
- Service information supported by public sources is identified in the article. Final prescribing decisions are made during consultation.
Points to compare before choosing treatment
| Medicine or route | Differences explained in this guide |
|---|---|
| Finasteride and dutasteride | Reduce DHT formation. Medicines for male AGA must not be passed to women. |
| Topical minoxidil | Supports hair growth. Follow the topical product’s instructions and its assessment period. |
| Combinations containing oral minoxidil | Oral minoxidil is unapproved in Japan. Its approval status and risks differ from topical treatment; check all ingredients and avoid duplication. |
This table summarizes the article. It does not establish the clinic’s actual products, prices or an individual prescription. Read each medicine’s information for directions and precautions.
What the medicine is
Finasteride and dutasteride reduce DHT production, while topical minoxidil supports hair growth. Different actions mean more content or more ingredients are not necessarily better.
Eligible patients and approved indications
Distinguish male pattern hair loss from female pattern hair loss, alopecia areata and sudden shedding. Do not repurpose male AGA 5α-reductase inhibitors for women.
Source: Medicine-specific primary documentation. The product used by the clinic is not assumed to be identical to the formulation in this documentation.
Treatment limitations and when diagnosis is needed
Full restoration cannot be guaranteed, and this is not treatment assessed over a few days. Do not assume scarring or inflammatory hair disease is AGA. Consider in-person care for scalp symptoms.
Formulations and basic directions
Follow each medicine’s prescribing instructions and topical directions. Distinguish approved Japanese single-ingredient products from combinations containing unapproved ingredients. Do not add finasteride, dutasteride or minoxidil yourself and duplicate treatment.
Source: Medicine-specific primary documentation. The product used by the clinic is not assumed to be identical to the formulation in this documentation.
Timing of response and decisions about continuation
Finasteride and dutasteride effects are usually assessed after approximately 6 months of continued use. Follow each topical product’s assessment period too, comparing consistent photographs and examination findings. Periodically assess need rather than continuing indefinitely.
Side effects and symptoms to watch for
Check sexual-function changes and liver function with 5α-reductase inhibitors, and scalp irritation with topical minoxidil. Oral minoxidil raises cardiovascular concerns such as edema or palpitations; topical approval does not establish oral safety.
Source: Medicine-specific primary documentation. The product used by the clinic is not assumed to be identical to the formulation in this documentation.
When to stop and seek medical attention
Jaundice, marked fatigue, chest pain, breathing difficulty or pronounced edema require prompt assessment. Tell a doctor about severe depressed mood or sexual-function changes before continuing.
Restrictions and interactions
Check ingredient-specific restrictions concerning women, children, pregnancy, breastfeeding, liver disease, heart or kidney disease and blood-pressure medicines. Disclose finasteride or dutasteride use for PSA testing.
Source: Medicine-specific primary documentation. The product used by the clinic is not assumed to be identical to the formulation in this documentation.
Pregnancy, breastfeeding and patient precautions
Do not give male AGA oral medicines to women, including pregnant or breastfeeding women. Take care handling broken finasteride tablets or leaking dutasteride capsules.
Additional care
Avoid vigorous scalp rubbing and support sleep and diet. Lifestyle improvements alone do not replace medical AGA treatment; sudden shedding warrants checks for medicines, other diseases and nutritional changes.
Storage and quality checks
Follow the actual label for each product. Check all ingredients in combinations, and concentration and eligible users for topical products. Personal imports without instructions are not managed equivalently to legitimate prescriptions.
Differences from other medicines and treatments
Consider progression-suppressing oral medicines separately from hair-growth-supporting topical treatment. The Japanese Dermatological Association’s 2017 guideline recommends topical minoxidil and states oral minoxidil should not be performed. Clinic provision of oral combinations differs from society recommendations and requires explanation of Japanese unapproved status and risks.
Discussing consultation and prescribing with SWIFT
SWIFT’s official AGA/FAGA page lists Hair Revival, Hair Revival-d, women’s Hair Revival-FF and topical minoxidil. Do not describe combination provision as sale of each ingredient’s approved Japanese single-ingredient product. Confirm prices and product information on the official page and during consultation.
Detailed information about each medicine
Frequently asked questions
For Hair loss medicines, is consultation unnecessary online?
A consultation is required. Symptoms may also warrant in-person care or additional tests.
For Hair loss medicines, are all combination tablets approved in Japan?
Approval of a single ingredient differs from approval of a combination. Oral minoxidil is unapproved in Japan.
For Hair loss medicines, can women use the same medicines?
Do not repurpose finasteride or dutasteride intended for men. Check the diagnosis and formulation.
Medical supervision
Dr Masashi Morita (Board-certified specialist and supervising physician, Japanese Urological Association / Board-certified specialist, Japan Endocrine Society / Doctor of Medical Science).